Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity
- PMID: 9852972
- DOI: 10.1086/514259
Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity
Abstract
Varicella-zoster virus (VZV) latency in human dorsal root ganglia is characterized by the transcription of large regions of its genome and by the expression of large amounts of some polypeptides, which are also expressed during lytic cycles. The immediate early 63 protein (IE63) is a virion component expressed very early in cutaneous lesions and the first viral protein detected during latency. Immune response against IE63 has been evaluated among naturally immune adults with a history of chickenpox: Specific antibodies were detected in serum, and most subjects who had a T cell proliferation with unfractionated VZV antigens had T cell recognition of purified IE63. The cytotoxic T cell (CTL) response to IE63 was equivalent to CTL recognition of IE62, the major tegument component of VZV, whose immunogenicity has been previously described. T cell recognition of IE63 and other VZV proteins is one of the likely mechanisms involved in controlling VZV reactivation from latency.
Similar articles
-
Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes.J Immunol. 1997 Sep 15;159(6):2802-6. J Immunol. 1997. PMID: 9300702
-
Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation.Vaccine. 2002 Feb 22;20(11-12):1593-602. doi: 10.1016/s0264-410x(01)00486-8. Vaccine. 2002. PMID: 11858867
-
Immunohistochemical identification of varicella-zoster virus gene 63-encoded protein (IE63) and late (gE) protein on smears and cutaneous biopsies: implications for diagnostic use.J Med Virol. 1995 Dec;47(4):342-7. doi: 10.1002/jmv.1890470409. J Med Virol. 1995. PMID: 8636701
-
Pathway of viral spread in herpes zoster: detection of the protein encoded by open reading frame 63 of varicella-zoster virus in biopsy specimens.Arch Virol Suppl. 2001;(17):109-19. doi: 10.1007/978-3-7091-6259-0_12. Arch Virol Suppl. 2001. PMID: 11339540 Review.
-
The role of varicella zoster virus immediate-early proteins in latency and their potential use as components of vaccines.Arch Virol Suppl. 2001;(17):81-9. doi: 10.1007/978-3-7091-6259-0_9. Arch Virol Suppl. 2001. PMID: 11339554 Review.
Cited by
-
Herpes simplex virus and varicella zoster virus, the house guests who never leave.Herpesviridae. 2012 Jun 12;3(1):5. doi: 10.1186/2042-4280-3-5. Herpesviridae. 2012. PMID: 22691604 Free PMC article.
-
Different Clinical Presentations and Outcomes of Disseminated Varicella in Children With Primary and Acquired Immunodeficiencies.Front Immunol. 2020 Nov 5;11:595478. doi: 10.3389/fimmu.2020.595478. eCollection 2020. Front Immunol. 2020. PMID: 33250898 Free PMC article.
-
Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.J Infect Dis. 2015 Oct 1;212(7):1022-31. doi: 10.1093/infdis/jiv164. Epub 2015 Mar 17. J Infect Dis. 2015. PMID: 25784732 Free PMC article.
-
A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation.J Gen Virol. 2015 Jul;96(Pt 7):1581-602. doi: 10.1099/vir.0.000128. Epub 2015 Mar 20. J Gen Virol. 2015. PMID: 25794504 Free PMC article. Review.
-
Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.Clin Diagn Lab Immunol. 2001 Sep;8(5):871-9. doi: 10.1128/CDLI.8.5.871-879.2001. Clin Diagn Lab Immunol. 2001. PMID: 11527795 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources